Shanghai Haoyuan Chemexpress Co. Ltd. Class A
SSSE:68813183.99
CNY
+1.97
(+2.40%)
ISIN
CNE1000051J4
Return %
Stock
S&P 500
1Y
4.95
14.20
3Y
95.81
81.12
5Y
-25.89
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Bao Fu Zheng
- Full Time Employees
- 4,195
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- No. 3 Building, No. 1999 Shanghai SH China 201203
- IPO Date
- Jun 8, 2021
- Website
- chemexpress.com.cn
- Similar Companies
- Business
- Shanghai Haoyuan Chemexpress Co., Ltd. specializes in research, development, and manufacturing of pharmaceutical intermediates and small molecule drugs. Its product portfolio includes active pharmaceutical ingredients (APIs), API intermediates, vitamin D series compounds, contract research organization (CRO) building blocks, and life bioscience compounds. The company also offers end-to-end contract development and manufacturing organization (CDMO) services for small molecules and new modalities such as antibody-drug conjugates (ADCs), peptides, and proteolysis targeting chimeras (PROTACs). Its comprehensive services cover discovery to commercialization support, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs, and drug products. Founded in 2006 and headquartered in Shanghai, China, Shanghai Haoyuan Chemexpress operates globally with a focus on pharmaceutical and biotech industries. It has expanded its operational footprint with the recent opening of a new GMP ADC One-Stop CDMO manufacturing site in Chongqing in March 2025. This 56,000 square meter state-of-the-art facility enhances its capability to provide integrated ADC/XDC CDMO solutions, including antibody drug substance GMP manufacturing with an annual design capacity of 8,000 liters, payload-linker GMP manufacturing with over 80 different payloads, bioconjugation, and drug product manufacturing. The company has made significant strides in expanding its production capacity and service offerings. In 2025, its reported operating revenue increased by 24.2% year-over-year to RMB 1.311 billion in the first half, with substantial net profit growth. Strategic investments in R&D account for approximately 10% of revenue, supporting innovation in chemical synthesis, novel compounds, and complex chiral molecules. Its business model emphasizes a “product+service” approach to accelerate drug development timelines and support commercialization globally. Shanghai Haoyuan Chemexpress maintains strong quality compliance systems aligned with ICH guidelines, ISO 9001 certifications, and GMP standards, ensuring high regulatory standards across its production sites. It serves a broad customer base including pharmaceutical developers, biotech firms, and global partners across more than 35 countries, positioning itself as a leader in specialty chemicals and pharmaceutical intermediates. The company is publicly listed on the Shanghai Stock Exchange under ticker 688131.SS. Its strategic focus on innovation, high-quality manufacturing, and expanding capacities in cutting-edge areas like ADCs reflects its commitment to supporting complex drug development and manufacturing needs worldwide.